Co-Authors
This is a "connection" page, showing publications co-authored by APOSTOLIA MARIA TSIMBERIDOU and DAVID VINING.
Connection Strength
1.550
-
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78.
Score: 0.226
-
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. Cancers (Basel). 2022 Mar 04; 14(5).
Score: 0.216
-
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3584-3594.
Score: 0.204
-
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. Ther Adv Med Oncol. 2021; 13:17588359211001538.
Score: 0.202
-
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21.
Score: 0.202
-
Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma. JCO Precis Oncol. 2018; 2.
Score: 0.173
-
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885.
Score: 0.169
-
Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther. 2011 Jan; 10(1):209-17.
Score: 0.099
-
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945.
Score: 0.059